Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | MIF | P14174 | 4/20 | 0.40 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.38 |
| ▸ | CD74 | P04233 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13160180 | 0.81 | NOTUM (0.51) | AMY1ANOTUMESRRAKCNH2 | |
| SCHEMBL13183607 | 0.81 | NOTUM (0.53) | RXRAGRIN1GRIN2BPTGS2NOTUM | |
| SCHEMBL9729936 | 0.79 | FLT3 (0.46) | RXRAGRIN1GRIN2BPTGS2MIF | |
| SCHEMBL13119830 | 0.79 | P2RX7 (0.50) | PTGS2MIFNOTUMESRRACD74 | |
| SCHEMBL26326038 | 0.77 | RXRA (0.47) | RXRAGRIN1GRIN2BPTGS2S1PR1 | |
| SCHEMBL19589440 | 0.77 | MAOA (0.50) | RXRAGRIN1GRIN2BNOTUMESRRA | |
| SCHEMBL25898936 | 0.77 | ESRRA (0.48) | S1PR1AMY1ANOTUMESRRA | |
| SCHEMBL23008630 | 0.76 | CYP1B1 (0.37) | RXRAGRIN1GRIN2BEGLN2NOTUM | |
| SCHEMBL22185933 | 0.75 | NOTUM (0.55) | RXRAGRIN1GRIN2BPTGS2AMY1A | |
| SCHEMBL24908501 | 0.75 | NOTUM (0.55) | NOTUMKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | Arvinas, Inc. | 2021-01-14 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009528-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | RXRA 1279/4885GRIN1 598/4885GRIN2B 950/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | RXRA 1335/4885GRIN1 585/4885GRIN2B 938/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | RXRA 510/4885GRIN1 2085/4885GRIN2B 1726/4885 |
| US-11236051-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, ADRM1, CRBN | RXRA 1279/4885GRIN1 598/4885GRIN2B 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.